| about us | contact us | links | sitemap |
 |
||||||||
| home | forum | studies | brain games | ||||||||
 |
||||||||
|
5-HTP
|
Acetyl L-Carnitine
|
Alpha GPC |
Alpha Lipoic Acid
| Aniracetam
|
Ashwagandha | Centrophenoxine |
||||||||
  |
Lee CR, Benfield P. Adis International
Limited, Auckland, New Zealand. Aniracetam is a member
of the nootropic class of drugs, which have possible cognition
enhancing effects. It appears to positively modulate metabotropic
glutamate receptors and
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-sensitive
glutamate receptors, and may facilitate cholinergic transmission,
effects which are possibly related to its mechanism of action.
Results from trials in elderly patients with mild to moderate
cognitive impairment due to senile dementia of the Alzheimer type
suggest that aniracetam may be of benefit, with further trials
required to confirm its efficacy profile and to define more
precisely those patients most likely to respond to treatment.
Aniracetam 1500 mg/day was significantly more effective than placebo
in all tests at 4 and 6 months, and in a further 6-month trial was
more effective than piracetam 2400 mg/day in 8 of 18 tests.
Preliminary evidence in the treatment of patients with cognitive
impairment of cerebrovascular origin suggests aniracetam may also be
of benefit in this condition. Whilst incidence rates of adverse
effects are not yet available, data from trials suggest aniracetam
is well tolerated. In particular, aniracetam does not appear to
cause increases in liver enzyme levels. The evaluation of drugs for
patients with senile cognitive disorders is a difficult area and
therapeutic options are currently limited. Preliminary evidence of
the potential benefits and good tolerability profile of aniracetam
support continued evaluation of its use in patients with mild to
moderate senile dementia of the Alzheimer type.
|
  |
||||||
 |
||||||||
